Orlinger Klaus 4
4 · HOOKIPA Pharma Inc. · Filed Jan 21, 2020
Insider Transaction Report
Form 4
Orlinger Klaus
Sr. VP, Research
Transactions
- Exercise/Conversion
Common Stock
2020-01-16$0.10/sh+571$57→ 1,711 total - Sale
Common Stock
2020-01-16$11.56/sh−1,711$19,781→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-01-16−571→ 14,530 totalExercise: $0.10Exp: 2026-12-31→ Common Stock (571 underlying) - Exercise/Conversion
Common Stock
2020-01-16$0.10/sh+1,140$114→ 1,140 total - Sale
Common Stock
2020-01-21$12.02/sh−6,789$81,592→ 0 total - Exercise/Conversion
Common Stock
2020-01-21$0.10/sh+6,789$679→ 6,789 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-01-16−1,140→ 0 totalExercise: $0.10Exp: 2026-12-31→ Common Stock (1,140 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-01-21−6,789→ 7,741 totalExercise: $0.10Exp: 2026-12-31→ Common Stock (6,789 underlying)
Footnotes (2)
- [F1]This option is fully vested and exercisable.
- [F2]25% of this option vested and became exercisable on January 1, 2018, with the remainder vesting in 12 equal quarterly installments thereafter.